• Biomolecules & Therapeutics
• /
• v.2 no.4
• /
• pp.343-346
• /
• 1994

In vivo activity of recombinant human erythropoietin (rh-EPO) has been examined using polycythemic model in mice and acute hemorrhage model in rats. The number of reticulocytes in blood stream was increased after a single injection of rh-EPO depending on the dosage of rh-EPO in polycythemy model. It seemed that optimal dose of rh-EPO for polycythemic mice was around 1-10 U/kg. Rh-EPO also showed the effectiveness for increase of reticulocyte numbers both in male and female rats after bleeding. The number of reticulocytes and the change of hemoglobin concentration in the blood stream of normal rats has been examined after injection of rh-EPO. The maximum value of reticulocyte was observed on the 6th day of the injection in these normal rats. In addition, the increase of reticulocyte and the concentration of hemoglobin were dependent on the dosage of rh-EPO. The increase of hemoglobin concentration was continued to the 9th day after injection. In this study, the efficacy of rh-EPO was confirmed in both mice and rats.

• The Korean Journal of Nuclear Medicine
• /
• v.9 no.2
• /
• pp.39-46
• /
• 1975

It is the purpose of this paper to design the most preferable method of erythropoietin bioassay in Korea. Bioassay utilizing polycythemic mice are currently in general use for the indirect determination of erythropoietin. Assay animals are usually prepared either by transfusion or by exposure to reduced oxygen tension in specially constructed chamber. We prepared the polycythemic, mice by the specially constructed hypobaric chamber. We observed weights and hematocrits of the mice in the hypobaric chamber, then hematocrits and 72 hours $^{59}Fe$ red cell upatke ratio of the polycythemic mice induced by hypoxia after removal from the hypobaric chamber. We designed the method of erythropoietin bioassay according to the results obtained by above experiments. Then we measured the 72 hours $^{59}Fe$ red cell uptake ratio of the polycythemic mice with normal saline, normal plasma and anemic plasma according to the method we designed. The results are followed: 1. The hematocrits of the mice in hypobaric chamber increased to 74% in 14 days It is preferable to maintain the pressure of the chamber to 400mmHg for first 4 days then 300mmHg for last 10 days to reduce the death rate and time consuming in hypobaric chamber. 2. After removal from the hypobaric chamber, the 72 hours $^{59}Fe$ red cell uptake ratio decreased rapidly and maintained the lowest level from the fourth day to tenth day. 3. We design the method of erythropoietin bioassay according to the results of above experiment and to the half life of erythropoietin. 4. The Korean product S9Fe is mixture of $^{59}Fe\;and\;^{55}Fe$. And the $^{59}Fe$ red cell uptake ratio in normal mice was far less with Korean product $^{59}Fe$ than with pure $^{59}Fe$ of foreign product. So it is desirable to use pure $^{59}Fe$ in this method of erythropoietin bioassay. 5. Considering the cost, the technique, the time consuming and the sensitivity it is the most preferable method of erythropoietin bioassay in Korea using hypobaric chamber to induce the polycythemia.

• Biomolecules & Therapeutics
• /
• v.6 no.3
• /
• pp.312-316
• /
• 1998

Efficacy and in vivo bioassay of recombinant human erythropoietin (rho-EPO), was investigated. Efficacy studies were conducted in normal, and cisplatin-induced anemic rats. Normal and anemic animals were treated intravenously with rhu-EPO for 5 days, and the changes in the number of red blood cells (RBC), hemoglobin concentration (Hb), hematocrit value (Hct) and percentage reticulocyte value (Ret, reticulocyte/RBC) were examined. In normal rats, rho-EPO significantly increased RBC, Hb, Hct and Ret at the doses of 50∼ 1,250 lU/kg/day in a dose-dependent fashion. Cisplatin-induced anemic rats showed significant increase of RBC, Hb, Hct and Ret after administration of rho-EPO (50-200 lU/kg/day) in a dose-dependent manner. These changes of hematological parameters disappeared gradually after cessation of the treatment. The in vivo bioassay results in polycythemic mice showed that rho-EPO had 90% of bioactivity compared to NIBSC standard rhu-EPO. These results suggest that rho-EPO might be useful for the therapy of anemia originated from renal failure and chemotherapy-induced anemia.